The GLP-1 Gold Rush Ran Out of Gold

There's a reason you see a new telehealth service advertising GLP-1 weight loss drugs every week. About 19 million Americans are taking these medications right now, and the total addressable market runs past $100 billion — a number that makes every health-tech startup from tiny private companies like Meant Health — a privately run clinician-reviewed weight-management platform — to public platforms with billions in market cap, race to set up shop. It's the kind of number that makes every health-tech startup, from tiny private companies like Meant Health — a privately run clinician-reviewed weight-management platform — to public platforms with billions in market cap, race to set up shop.

The problem isn't whether the demand is real. It's whether the business model can earn money, or whether the cash flow simply passes through — with the platform collecting a small mark-up on drugs it doesn't manufacture, for patients who cancel as soon as they find a cheaper option.

Here's what happened to the economics this year.

The compounding loophole closed

For two years, the GLP-1 telehealth boom ran on a regulatory loophole. Drugs like semaglutide — sold under brand names Ozempic and Wegovy — were so hard to find that the FDA declared national shortages. During a declared shortage, compound pharmacies could legally mix their own versions, and telehealth companies sold those compounds to patients at very high margins.

Hims & Hers, the largest public telehealth platform in this space, built its weight-loss growth on this model. In the second quarter of 2025, the company's gross margin on the business ran around 76%.

Then the shortages ended, the regulators woke up, and the pharmaceutical companies sued.

The FDA declared the semaglutide shortage resolved in February 2025, closing the compounding window. By the spring of 2026, the agency was sending more than 30 warning letters to telehealth companies for making false or misleading claims about compounded products. Novo Nordisk filed dozens of lawsuits against entities selling knockoff semaglutide. Eli Lilly sued multiple companies including Mochi Health for promoting compounded tirzepatide. The HHS Office of Inspector General launched a referral into Hims & Hers over its marketing practices.

In February 2026, the stock fell 22% in a single day when Hims & Hers announced it would stop selling compounded semaglutide. On March 9, 2026, the company formalized the pivot: a new collaboration with Novo Nordisk to sell branded Ozempic and Wegovy, with compounded drugs limited to a small subset of patients whose clinical needs can't be met by FDA-approved products.

The compounding model was essentially an arbitrage — buy cheap generic active ingredients from overseas, compound them, sell at a steep markup through a frictionless direct-to-consumer platform. When the FDA said "those are not the same as approved drugs and you can't pretend they are," the arbitrage vanished.

What the branded model actually earns

You can see the margin difference in the financials.

In the first quarter of 2026, Hims & Hers swung from a $49.5 million profit to a $92 million net loss. Revenue was $608 million, up just 4% from a year earlier. Gross margin dropped from 73% to 65% — a 10-percentage-point decline in one quarter. By the second quarter, margins had fallen further to 64%, down from 76% a year prior. Another $86 million net loss. The company wrote down compounded drug inventory and incurred restructuring costs as the old product line came down.

Here's what the numbers look like side by side:

Metric	Q2 2025	Q2 2026	Change
Revenue	$545M	$753M	+38%
Gross margin	76%	64%	-12 pts
Net income	$42.5M	($86.3M)	-$129M
Subscribers	2.4M	2.9M	+19%
Monthly revenue per subscriber	$76	$92	+21%

Revenue is growing — fast. But it's growing through volume, not margins. More subscribers, higher spending per subscriber, but the company is earning a lot less on every dollar of that revenue.

The branded model works differently. Hims & Hers doesn't make Ozempic or Wegovy. Novo Nordisk does. The platform negotiates a price from the manufacturer, marks it up, and delivers it through its subscription system. The spread between what it pays Novo Nordisk and what it charges the patient is the revenue. And that spread is narrow compared to the compounding days.

Management expects the margin pressure to be temporary, pointing to scale, expanding product lines, and a return to profitability over time. The second-quarter revenue beat of $753 million versus the $545 million from a year earlier signals the volume growth is real even as the economics tighten.

That is a reasonable target if subscriber growth holds and the branded GLP-1 assortment expands. But it's a fundamentally different business from the one that posted 76% gross margins a year ago. This is now a volume and retention play on someone else's drug, not a high-margin compounding operation.

Where the cash actually comes from

For an investor focused on whether this business produces real cash, there are two different questions.

The first is whether the platform can generate enough cash flow to survive. Hims & Hers sits on $610 million in cash with $3.3 billion in total debt — most of it coming from the SPAC merger that took the company public. Free cash flow over the trailing twelve months was $62 million. The company can operate, but it cannot yet fund growth from cash flow alone.

The second is whether the cash flow will ever become large enough to matter for an income portfolio. At current guidance, adjusted EBITDA of roughly $300 million on $3.2 billion in revenue is a durable but modest engine. The company trades at a $6.4 billion market cap. There is no dividend, no buyback, and management has committed the cash to international expansion across the UK, Canada, and Europe — growth that is being funded through acquisitions rather than organic cash flow.

Compare this to GoodRx (GDRX), which entered the GLP-1 telehealth space with a $39-per-month subscription launched in late 2025. GoodRx already generates $132 million in trailing free cash flow, with $296 million in cash on the balance sheet and only $191 million in net debt. Its core drug-discount-card business — which generated $200 million in revenue in Q2 2026 — produces cash today. The weight-loss telemedicine add-on is a new revenue stream layered on top of an already-profitable platform. The trade-off is scale: GoodRx's market cap of $1.2 billion reflects a company that earns money now, while Hims & Hers's $6.4 billion reflects a bet on future subscriber scale.

The subscription friction no one talks about

The economics of any GLP-1 telehealth platform depend on one thing: how long a patient stays subscribed.

These drugs work by creating a continuous appetite-suppressing effect. When patients stop taking them, the appetite returns and weight typically comes back. That should, in theory, lock patients into a recurring relationship. But the financial reality is messier.

Most programs charge patients $150 to $500 per month before medication costs, and the drug itself is billed separately. In 2026, cash-pay prices for branded GLP-1s have dropped significantly from the $1,000-plus list prices seen in earlier years. Eli Lilly and Novo Nordisk now sell directly to patients through their own platforms — LillyDirect and NovoCare. When the manufacturer can offer the same drug at a lower price without the middleman, patient retention through a third-party platform becomes a marketing problem, not just a clinical one.

Hims & Hers addresses this with a "Weight Loss Warranty" — a full refund if weight-loss goals aren't met — and unlimited clinician calls. GoodRx undercuts on price at $39 for the telehealth subscription. The real competitive moat here is convenience, clinical oversight, and the bundled experience of labs, coaching, and support. But none of these are proprietary or exclusive. They are service differentiators in a market where the actual product — a GLP-1 drug — is made by two companies, both of whom are building their own direct-to-patient channels.

What this means for the investment case

The GLP-1 telehealth story is not a story about yield — none of these companies pay a dividend. It is a story about whether a platform business model, built during a regulatory accident, can survive the accident closing and still compound at the rate the market expects.

Hims & Hers is the most visible test case. The company trades at $6.4 billion, roughly 2.5 times its current revenue. Forward P/E sits at 35x. It is losing money, carries $3.3 billion in debt, and has just completed a painful pivot that erased its high-margin product line. The growth is real: 2.9 million subscribers, 38% revenue growth, and a credible path to $3 billion in annual revenue. But the valuation assumes that path continues for years, that international expansion pays off, that retention holds against manufacturer-direct competition, and that the company eventually returns to profitability.

For an income investor, the practical answer is straightforward: this is not a business that pays you to wait. The cash flow exists but is reinvested, the debt is significant, and the dividend question is years away. If you believe in the long-term growth of telehealth-delivered weight management, the branded-drug model is cleaner and more defensible than the compounding one that preceded it — but the margin expansion that made the compounding era so profitable won't come back.

The lower prices these platforms have driven into the market are one of the real wins for patients and for anyone watching these stocks as a future addition. The $39 GoodRx subscription, the direct manufacturer channels, the compressed list prices — the arbitrage that fed telehealth margins is the same force making GLP-1s more accessible. That's good for healthcare. It means the gold rush was real, but the gold was the arbitrage itself, and that window has closed.